All In Biotech

Drug Trial Radar · NCT07683754

T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd

A Global, Interventional, Open-label Trial of T-DXd-based Therapy Followed by Palbociclib, Endocrine Therapy and Dual HER2 Blockade in First-line HER2+/ HR+ Advanced or Metastatic Breast Cancer and Retreatment With T-DXd (DB-Guide)

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Nov 4, 2026

Primary completion

Jul 4, 2030

Study completion Aug 28, 2030

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
AstraZeneca
First posted
Jul 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate a structured sequential treatment strategy starting with T-DXd + pertuzumab upfront therapy, followed by an optimized maintenance therapy with dual HER2+blockade + CDK4/6i + ET and the opportunity to retreat with T-DXd once patients progress under maintenance aimed to maximizing disease control, optimizing tolerability, and preserving T-DXd as a future therapeutic option, while ensuring participant safety and regulatory compliance in participants with HER2+/HR+ advanced/metastatic breast cancer.

Conditions

  • Advanced Breast Cancer
  • Metastatic Breast Cancer
  • HER2 Positive
  • HR Positive

Interventions

  • Trastuzumab deruxtecanDrug

    Upfront treatment: One IV infusion Q3W 5.4 mg/kg (starting dose) on Day 1 of each 21-day cycle T-DXd Retreatment: One IV infusion Q3W 5.4 mg/kg (starting dose) on Day 1 of each 21-day cycle \*Dose reductions implemented during Upfront treatment phase will be maintained.

  • TrastuzumabDrug

    Maintenance treatment: One IV infusion Q3W 6 mg/kg on Day 1 of each 21-day cycle

  • PertuzumabDrug

    Upfront treatment: One IV infusion Q3W loading dose of 840 mg, then 420 mg Q3W thereafter on Day 1 of each 21-day cycle Maintenance treatment: One IV infusion Q3W 420 mg on Day 1 of each 21-day cycle

  • Endocrine TherapyDrug

    Aromatase inhibitors or fulvestrant administered as approved product label

  • PalbociclibDrug

    Maintenance treatment: Daily (3 out of 4 weeks, Q4W) oral 125 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) Rate at 24 MonthsTime frame: From start of Upfront Treatment phase until disease progression (PD) or death, whichever occurs first, up to approximately 24 months

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Maryland Oncology Hematology, P.A.

    Columbia, Maryland · Recruiting

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • Texas Oncology - West Texas

    El Paso, Texas · Recruiting

  • Texas Oncology - San Antonio

    New Braunfels, Texas · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.